📊 NGNE Key Takeaways
Is Neurogene Inc. (NGNE) a Good Investment?
Neurogene is a pre-revenue pharmaceutical development stage company with significant operating losses (-$103.3M) and substantial cash burn (-$78.4M FCF), providing only ~1.3 years of cash runway at current burn rates. While the company maintains a strong balance sheet with $103.8M cash and no meaningful debt, and losses are improving modestly year-over-year, the absence of commercial revenue and high execution risk make fundamental valuation untenable until pipeline progress demonstrates viability.
Neurogene is a pre-revenue developer with a strong balance sheet—ample cash, minimal liabilities, and no debt—providing a reasonable runway to progress programs. However, operating losses and cash burn remain substantial and net losses appear elevated year over year. Until there is clear evidence of clinical milestones translating into partnerships or initial revenue, fundamentals are neutral.
Why Buy Neurogene Inc. Stock? NGNE Key Strengths
- Strong liquidity position with $103.8M cash and 16.56x current ratio
- Clean capital structure with zero long-term debt and minimal liabilities
- Net losses improving 20.2% YoY indicating potential progress toward profitability
- Moderate insider trading activity (15 Form 4 filings in 90 days) suggests engagement
- Robust liquidity and 16.56x current ratio
- No long-term debt and low liabilities
- Large equity base relative to assets/liabilities
NGNE Stock Risks: Neurogene Inc. Investment Risks
- Pre-revenue stage with zero commercial sales generating complete pipeline dependency
- Cash runway of approximately 1.3 years at current -$77.2M annual operating burn rate
- Negative return on equity (-34.1%) and assets (-31.3%) indicating capital inefficiency
- All profitability metrics non-existent; company survival contingent on pipeline approval and commercialization
- Zero revenue with continued large net losses
- High operating cash burn shortening runway
- Execution/clinical and financing risk leading to potential dilution
Key Metrics to Watch
- Quarterly cash burn rate trend and cash balance depletion schedule
- Clinical pipeline advancement milestones and regulatory approval progress
- Operating expense management and ability to extend runway through fundraising
- Cash & equivalents
- Operating cash flow (burn rate)
Neurogene Inc. (NGNE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 16.56x current ratio provides a solid financial cushion.
NGNE Profit Margin, ROE & Profitability Analysis
NGNE vs Healthcare Sector: How Neurogene Inc. Compares
How Neurogene Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neurogene Inc. Stock Overvalued? NGNE Valuation Analysis 2026
Based on fundamental analysis, Neurogene Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neurogene Inc. Balance Sheet: NGNE Debt, Cash & Liquidity
NGNE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neurogene Inc.'s revenue has declined by 96% over the 5-year period, indicating business contraction. The most recent EPS of $-4.28 indicates the company is currently unprofitable.
NGNE Revenue Growth, EPS Growth & YoY Performance
NGNE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$16.9M | $-0.99 |
| Q2 2025 | N/A | -$16.9M | $-1.05 |
| Q3 2024 | N/A | -$11.9M | $-1.19 |
| Q2 2024 | N/A | -$11.9M | $-1.09 |
| Q3 2019 | $25.0M | -$15.0M | N/A |
| Q2 2019 | $25.0M | -$1.0K | $-0.09 |
| Q3 2018 | $25.0M | -$11.8M | N/A |
| Q2 2018 | $25.0M | $2.9M | $0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Neurogene Inc. Dividends, Buybacks & Capital Allocation
NGNE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neurogene Inc. (CIK: 0001404644)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NGNE
What is the AI rating for NGNE?
Neurogene Inc. (NGNE) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NGNE's key strengths?
Claude: Strong liquidity position with $103.8M cash and 16.56x current ratio. Clean capital structure with zero long-term debt and minimal liabilities. ChatGPT: Robust liquidity and 16.56x current ratio. No long-term debt and low liabilities.
What are the risks of investing in NGNE?
Claude: Pre-revenue stage with zero commercial sales generating complete pipeline dependency. Cash runway of approximately 1.3 years at current -$77.2M annual operating burn rate. ChatGPT: Zero revenue with continued large net losses. High operating cash burn shortening runway.
What is NGNE's revenue and growth?
Neurogene Inc. reported revenue of $0.0.
Does NGNE pay dividends?
Neurogene Inc. does not currently pay dividends.
Where can I find NGNE SEC filings?
Official SEC filings for Neurogene Inc. (CIK: 0001404644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NGNE's EPS?
Neurogene Inc. has a diluted EPS of $-4.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NGNE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Neurogene Inc. has a SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NGNE stock overvalued or undervalued?
Valuation metrics for NGNE: ROE of -34.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NGNE stock in 2026?
Our dual AI analysis gives Neurogene Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NGNE's free cash flow?
Neurogene Inc.'s operating cash flow is $-77.2M, with capital expenditures of $1.2M.
How does NGNE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -34.1% (avg: 15%), current ratio 16.56 (avg: 2).